Edoardo Mannucci Andrea Giaccari Marco Gallo Giovanni Targher Basilio Pintaudi Riccardo Candido Matteo Monami ABSTRACT Aim In the Italian Society of Diabetology and the Italian Association of Clinical Diabetologists nominated an expert panel to develop guidelines for drug treatment of type diabetes After identifying the effects of glucose lowering agents on major adverse cardiovascular events MACEs all cause mortality and hospitalization for heart failure HHF as critical outcomes the experts decided to perform a systematic review and meta analysis on the effect of pioglitazone with this respect Methods A MEDLINE database search was performed to identify RCTs up to June st with duration weeks in which pioglitazone was compared with either placebo or active comparators The principal endpoints were MACE and HHF restricted for RCT reporting MACEs within their outcomes all cause mortality irrespective of the inclusion of MACEs among the pre specified outcomes Mantel Haenszel odds ratio MH OR with Confidence Interval CI was calculated for all the endpoints considered Results Eight RCTs were included in the analysis for MACEs and HF and patients in the pioglitazone and control group respectively and in that for all cause mortality and patients Pioglitazone neither significantly increased nor reduced the risk of MACE all cause mortality and HHF in comparison with placebo active comparators MH OR CI CI and CI respectively Pioglitazone was associated with a significant reduction of MACE in patients with prior cardiovascular events MH OR CI Conclusions This meta analysis showed no significant effects of pioglitazone on incident MACE all cause mortality and HHF Sources 